Ultragenyx Pharmaceutical Inc. said it believes data from a phase III study testing burosumab (KRN23), a recombinant fully human monoclonal IgG1 antibody, are sufficient to support a BLA filing this year in X-linked hypophosphatemia (XLH), a bone disease characterized by phosphate wasting due to excess activity of FGF23.